SLC18A2 and juvenile Huntington disease: Tetrabenazine is an approved inhibitor of VMAT2 for the treatment of chorea associated to Huntington's disease [99]. Salmeterol and ziprasidone are FDA-approved compounds able to inhibit VMAT2, which could potentially be repurposed for the symptomatic treatment of tardive dyskinesia and other hyperkinetic movements [102].